Niraparib
PALB2-Related Cancer Predisposition
Explore 13 assets in PALB2-Related Cancer Predisposition →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Qian Qin
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06392841CT.gov Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations | — | Withdrawn | — | — | — |
NCT05694715CT.gov Combination Therapy in Cancers With Mutations in DNA Repair Genes | — | Recruiting | — | — | — |
NCT05232006CT.gov PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers | — | Not Yet Recruiting | — | — | — |
NCT04584255CT.gov Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · PALB2-Related Cancer Predisposition
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | Qian Qin | P2 | B · 59 |
| Cis-Diamminedichloroplatinum Ii | University Health Network, Toronto | P2/3 | B |
| Prednisone | Qian Qin | P2 | CCC |
| Docetaxel | Qian Qin | P2 | CCC |
| Olaparib | Beth Israel Deaconess Medical Center | P2 | CCC |
| Tamoxifen | European Institute of Oncology | P2 | CCC |
| Dostarlimab | Dana-Farber Cancer Institute | P2 | CCC |
| Abiraterone | Qian Qin | P2 | CCC |
| Talazoparib | M.D. Anderson Cancer Center | P2 | CCC |
+4 more in the PALB2-Related Cancer Predisposition cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niraparib in PALB2-Related Cancer Predisposition. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-palb2-related-cancer-predisposition
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →